Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Evaluation of Toothpaste Effect in Volunteers With Dental Sensitivity

18. mai 2026 oppdatert av: Lacer S.A.

Comparative Clinical Trial to Evaluate the Efficacy of a Toothpaste in Subjects With Dental Hipersensitivity

The goal of this study is to learn if a toothpaste alone and together with mouthwash works to alleviate teeth hypersensitivity in adults. It will also learn about the safety of the product.

The main question it aims to answer is:

• Does the toothpaste help to improve signs of teeth hypersensitivity? Researchers will compare sensitive teeth toothpaste and use of sensitive teeth and mouthwash to a regular toothpaste to see if it works to improve teeth sensitivity.

Participants will:

  • Use assigned products daily for 14 days
  • Visit the clinic on the established days during 14 days for check-ups and evaluation

Studieoversikt

Studietype

Intervensjonell

Registrering (Faktiske)

71

Fase

  • Ikke aktuelt

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

      • Barcelona, Spania
        • Hospital Odontológico Universidad de Barcelona - Bellvitge

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

  • Voksen
  • Eldre voksen

Tar imot friske frivillige

Nei

Beskrivelse

Inclusion Criteria:

  • Healthy female and male participants (no specific gender distributions required)
  • Aged 18 years or older
  • Participants presenting dental hyperesthesia with at least two hypersensitive teeth with a verbal rating scale (VRS) score greater than or equal to 1 after tactile stimulation, and a Schiff Cold Air Sensitivity Scale score greater than or equal to 1 at the initial visit (T0).
  • Participants certifying the truthfulness of the personal data disclosed to the investigator.
  • Participants able to understand the language used at the investigation centre and comprehend the information provided by the investigator.
  • Participants able to follow the instructions provided by the investigator and comply with the study requirements and restrictions.
  • Pharmacological therapy (except for therapies listed under non-inclusion criteria) must have been stable for at least one month, with no changes expected or planned during the study
  • Commitment by the participants not to change the daily routine or lifestyle during the study.
  • Participants who have not taken part in any other similar clinical study in the previous six months.
  • Commitment by the participant not to use other oral hygiene products containing fluoride or ingredients such as hydroxyapatite during the study period.

Exclusion Criteria:

  • Participants currently participating or planning to participate in other clinical trials.
  • Participants deprived of liberty by administrative or judicial decision or under guardianship.
  • Participants who cannot be contacted in the event of an emergency.
  • Participants admitted to a healthcare or social institution.
  • Participants planning hospitalization during the study period.
  • Participants who have taken part in a similar study without respecting an adequate washout period (defined as the use of desensitizing agents within the last six months).
  • Participants under pharmacological treatments that modify the evaluation of dental sensitivity or are incompatible with the requirements of the study.
  • Participants with a history of active caries within the past 12 months or at risk for developing caries (e.g., multiple dental restorations, crowns with compromised margins) per examiners discretion.
  • Participants with known allergies or sensitivities to any components of the investigational product.
  • Women who are breastfeeding, pregnant, or unwilling to take the adequate contraceptive measures to avoid pregnancy during the study (for women of childbearing potential).
  • Participants with acute, chronic, or progressive pathologies (including diabetes, cardiovascular and metabolic conditions) incompatible with the study requirements.
  • Any tooth surface adjacent to those surfaces under investigation that in the opinion of the investigator have any other condition that produce symptoms confounding the evaluation of cervical dentin hypersensitivity.
  • Participants with a medical history or taking medication, or wearing physical items (e.g., orthodontic braces) that could interfere with the study.
  • Participants with a history of illegal drug use.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Annen
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Dobbelt

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Aktiv komparator: Vanlig tannkrem
Toothpaste was used two times a day (after meals) during 14 days
Eksperimentell: Desensitizing toothpaste
Toothpaste was used two times a day (after meals) during 14 days
Eksperimentell: Desensitizing toothpaste with mouthwash
Toothpaste and mouthwash were used two times a day (after meals) during 14 days

Hva måler studien?

Primære resultatmål

Resultatmål
Tidsramme
Change from Baseline in dentine sensitivity comparing desensitizing toothpaste versus active comparator at 14 days
Tidsramme: From enrollment to the end of use at 14 days
From enrollment to the end of use at 14 days

Sekundære resultatmål

Resultatmål
Tidsramme
Change in dentine sensitivity from baseline in dentine sensitivity comparing desensitizing toothpaste group versus desensitizing toothpaste and mouthwash group at day 14.
Tidsramme: From baseline to day 14
From baseline to day 14
Change from baseline in pH at 14 days
Tidsramme: From baseline to day 14
From baseline to day 14

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Sponsor

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

1. februar 2025

Primær fullføring (Faktiske)

30. april 2025

Studiet fullført (Faktiske)

30. april 2025

Datoer for studieregistrering

Først innsendt

11. mai 2026

Først innsendt som oppfylte QC-kriteriene

11. mai 2026

Først lagt ut (Faktiske)

18. mai 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

20. mai 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

18. mai 2026

Sist bekreftet

1. mai 2026

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

IPD-planbeskrivelse

Only summary of the results to support the publication will be shared. No complete study documents will be shared.

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere